---
layout: post
title:  "Early Goal-Directed Therapy (EGDT) in Sepsis Management: Time for a Shift in Practice?"
date:   2024-10-06
categories: sepsis
---

<img class="featuredImg" src="https://res.cloudinary.com/dn4n3lljr/image/upload/c_crop,w_1300,h_731,ar_16:9/v1728219458/ow/sepsis_g2rnpd.webp"/>

## Introduction

**Early Goal-Directed Therapy (EGDT)** was once the cornerstone of sepsis management following the landmark study by Rivers et al. in 2001. This protocol, which included early fluid resuscitation, blood pressure control, and oxygen delivery optimization, promised substantial mortality reduction in sepsis patients. However, subsequent trials such as **ProCESS**, **ARISE**, and **PROMISE** questioned the superiority of EGDT over usual care. This article advocates for a modified approach to sepsis management, which aligns with recent evidence and emphasizes a more flexible, patient-tailored treatment strategy.

## Background on EGDT

The traditional EGDT approach involves aggressive early resuscitation in the first six hours of sepsis diagnosis. This includes specific targets for **central venous pressure (CVP)**, **mean arterial pressure (MAP)**, and **central venous oxygen saturation (ScvO2)**. The idea behind this protocol was to reverse hypoperfusion and prevent organ dysfunction early in sepsis. However, while EGDT's impact was impressive in the early 2000s, evolving sepsis care, such as broader antibiotic usage and advancements in ICU support, have necessitated a re-evaluation of the protocol’s rigid approach.

## The Case for a Modified Approach

The subsequent clinical trials — **ProCESS** (2014), **ARISE** (2014), and **PROMISE** (2015) — have collectively shown that protocolized EGDT does not confer a mortality benefit over usual care. These studies used similar patient populations and tested standard care against the strict Rivers’ EGDT protocol. The conclusion from these trials was that mortality rates were similar across both groups, suggesting that the aggressive early resuscitation provided by EGDT is not superior to more individualized care.

### ProCESS Trial

The **ProCESS trial** randomized patients to receive either protocol-based EGDT, protocol-based standard care, or usual care. No significant difference was observed in 60-day mortality between the three groups, indicating that the strict targets in EGDT might not be necessary.

### ARISE Trial

Similarly, the **ARISE trial**, which focused on patients from Australia and New Zealand, found no significant mortality difference between those receiving EGDT and those receiving standard care. However, the study did emphasize that early antibiotics and initial fluid resuscitation remained critical.

### PROMISE Trial

The **PROMISE trial** in the UK also confirmed these findings, suggesting that the rigid application of EGDT does not provide additional benefits when compared to contemporary usual care.

## Why a Modified Approach is Better

Given the results of these pivotal trials, it is clear that the benefit of EGDT is not in its strict protocolization but in the early recognition and treatment of sepsis. The emphasis now is on individualized care that prioritizes the patient’s condition rather than adherence to specific resuscitation targets. The rigid goals of CVP, MAP, and ScvO2 are no longer seen as universally applicable, as they may not take into account individual variability in sepsis response.

### Tailored Resuscitation

Current evidence suggests that aggressive fluid resuscitation as mandated by EGDT may be harmful in some patients, especially those with heart failure or other fluid overload risks. A modified approach, such as using dynamic markers like stroke volume variation, echocardiography, and lactate clearance, offers a more individualized and patient-specific treatment plan.

### Focus on Source Control and Early Antibiotics

One of the key findings from these trials is that early antibiotics and source control remain critical components of sepsis management, with or without EGDT. The current **Surviving Sepsis Campaign** guidelines emphasize this approach, encouraging rapid identification and treatment of infection rather than adherence to rigid hemodynamic goals.

### Flexibility in Vasopressor Use

While EGDT emphasizes early vasopressor use to maintain MAP, more recent guidelines suggest a more flexible approach, starting vasopressors only when clinically indicated, rather than universally applying them to meet MAP targets early in resuscitation.

## Conclusion

In conclusion, while EGDT was revolutionary when first introduced, subsequent evidence has demonstrated that a more flexible, patient-centered approach to sepsis management is just as effective, if not more so. A modified approach, which emphasizes early identification, source control, and tailored resuscitation, is more in line with current evidence from high-quality trials. The **ProCESS**, **ARISE**, and **PROMISE** studies have made it clear that EGDT is not superior to standard care and that rigid hemodynamic goals are unnecessary. Moving forward, clinicians should focus on a dynamic, individualized approach to sepsis management that ensures early intervention without the constraints of outdated protocols.

## References

- The ProCESS Investigators. (2014). A Randomized Trial of Protocol-Based Care for Early Septic Shock. _New England Journal of Medicine_, 370(18), 1683-1693. [https://doi.org/10.1056/NEJMoa1401602](https://doi.org/10.1056/NEJMoa1401602)
- The ARISE Investigators. (2014). Goal-Directed Resuscitation for Patients with Early Septic Shock. _New England Journal of Medicine_, 371(16), 1496-1506. [https://doi.org/10.1056/NEJMoa1404380](https://doi.org/10.1056/NEJMoa1404380)
- The PROMISE Investigators. (2015). Process of Care in the UK: Protocol-Based Resuscitation for Sepsis. _Lancet_, 386(10006), 2059-2068. [https://doi.org/10.1016/S0140-6736(15)60006-9](https://doi.org/10.1016/S0140-6736(15)60006-9)
- Rivers, E., Nguyen, B., Havstad, S., et al. (2001). Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. _New England Journal of Medicine_, 345(19), 1368-1377. [https://doi.org/10.1056/NEJMoa010307](https://doi.org/10.1056/NEJMoa010307)
- Levy, M. M., Evans, L. E., & Rhodes, A. (2018). The Surviving Sepsis Campaign Bundle: 2018 update. _Intensive Care Medicine_, 44(6), 925-928. [https://doi.org/10.1007/s00134-018-5085-0](https://doi.org/10.1007/s00134-018-5085-0)
